Navigation Links
Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
Date:6/13/2008

The most common grade 3-5 adverse events, regardless of relation to treatment, were febrile neutropenia in 8 patients, and neutropenia and thrombocytopenia in 7 patients respectively. One patient died within 30 days of first induction treatment due to pneumonia.

Dr. Ghulam Mufti, Department Head and Professor of Hematological Medicine at the University of London King's College Hospital, and an investigator on the trial, said, "The activity demonstrated in this study is encouraging, particularly the complete responses observed in those patients that had received prior treatment for MDS." He concluded, "Despite recent advances in the treatment of MDS, most patients will relapse, and it is important that we continue to develop new therapies to treat these patients."

Alan Kessman, Chief Executive Officer, said, "These data demonstrate Cloretazine(R) (VNP40101M)'s potential utility in patients with high-risk MDS. We believe that this signal should be pursued with further clinical investigation to optimize the dose and schedule of Cloretazine(R) (VNP40101M) in this disease."

The Phase II trial started in March 2004 and was conducted in 14 sites in North America and Europe. Enrollment of the study was completed in May 2006.

The study was designed for patients over the age of 60 with previously untreated AML and high-risk MDS (patients were not to have received prior cytotoxic chemotherapy, excluding hydroxyurea, low-dose araC, decitabine, or 5-azacytidine). Study objectives were: (i) overall complete response rate measured as either complete remission (CR) or CRp, a complete response with incomplete platelet recovery; (ii) the toxicity; and (iii) pharmacokinetics of Cloretazine(R) (VNP40101M) in this patient population.

Patients received induction therapy of 600 mg/m2 of Cloretazine(R) (VNP40101M) in a thirty to sixty minute infusion. Second induction was permitted in patients with bone marrow improvement but residual disease. Patients wh
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
2. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
3. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
4. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
5. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
6. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
7. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
8. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
9. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
10. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... decision support to healthcare providers for behavioral health ... has secured $30 million in equity financing from ... C. Drosos , President and Chief Executive Officer. ... adoption and development of Assurex Health,s GeneSight ...
(Date:12/24/2014)... N.C. , Dec. 23, 2014  Endo Pharmaceuticals ... ENDP ) (TSX: ENL), and BioDelivery Sciences International, ... they have submitted a New Drug Application (NDA) for ... Drug Administration (FDA).  Buprenorphine HCl Buccal Film is under ... require daily, around-the-clock, long-term opioid treatment and for which ...
(Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has announced ... Market" report to their offering. ... focuses on the developments in the self-monitoring blood glucose ... Reimbursement analysis and the effects of competitive bidding have ... SMBG meters have been performed, based on the various ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5US Self-monitoring Blood Glucose Market 2
... Columbia, April 25, 2012  Enox Biopharma, Inc. CEO, John ... Device 360 Conference on Wednesday, April 25, 2012. The ... London, UK. The IN3 Medical Device ... medical device industry forum and networking meeting. The goal ...
... 2012 Masimo (NASDAQ: MASI ) ... to monitor oxygen saturation in newborns. The newly enhanced ... ® , and Inf Sensors ® are smaller ... and easier to apply for healthcare workers. ...
Cached Medicine Technology:Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London 2Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors 2Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors 3Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors 4Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors 5
(Date:12/26/2014)... 2014 Plugin and template developers from ... Plugin for Final Cut Pro X. , “TransPack Volume 5 ... to pull off an industry professional look” Said Christina Austin, ... on TransPack Volume 5, a new level of professionalism will ... of over 50 Final Cut Pro X transitions featuring organic ...
(Date:12/26/2014)... Parker & Sons, Inc. a reliable ... cooling and plumbing contractor services throughout Arizona announces ... 2014 with regard to air-conditioning systems. Residential and ... for its incredibly hot summers. Working with an ... details of a wide variety of systems made ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 The ... to 2023” focuses on the current treatment landscape, unmet ... cancer market. TS-1 is an anti-cancer drug which is ... orally and is also used for treating gastric cancer ... and otastat potassium. The drug was first approved in ...
(Date:12/25/2014)... 25, 2014 The short film “Color of ... in honor of a true 9/11 hero, Welles Remy Crowther. ... including the 24 hours of Nuremberg International Short Film Festival ... , Actress, screenwriter and director Luciana Lagana plays ... together with her husband, Gregory Graham - Graham ...
(Date:12/25/2014)... has updated its blog to provide professional shopping tips on wedding ... at LunaDress.co.uk come with big discounts, up to 80 percent off. ... out to be a most exciting memory and can show off ... to a wedding. On the updated fashion blog, ladies can now ... big day . , Going out with friends to a party ...
Breaking Medicine News(10 mins):Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2
... CT enterography in diagnosing fibrosis in pediatric patients with ... in detecting active inflammation, and a new study shows. ... Hospital in Boston, found that MR enterography was 77.6% ... enterography. MR enterography had an 82.1% accuracy rate ...
... BOSTON Noisy neighbors and broken-down elevators are common downsides ... to the list of hazards, according to research to be ... annual meeting in Boston. Studies have shown that tobacco ... to which this happens, however, is unclear. Researchers from ...
... chronic diseases and disorders that begin in infancy will ... research being presented on Saturday, April 28, 2012, at ... Pediatric Academic Societies (PAS) annual meeting in Room 302 ... session, "Life-course Research: State of the Art and Science," ...
... -- Driving can be a major factor in elderly people,s ... an expert says. If an older driver,s diminishing abilities ... to be dealt with compassionately to preserve the person,s dignity ... a geriatric specialist with the Harris County Hospital District in ...
... IV unresectable melanoma are now routinely genetically profiled for several ... for melanoma. Research has shown that mutations in the BRAF ... that are BRAF inhibitors. "We have found that a ... gene mutation quickly develop resistance to drugs that are BRAF ...
... (HealthDay News) -- People undergoing outpatient surgery should be warned ... new study that finds the risk is higher among groups ... obese. The University of Michigan researchers found that one ... outpatient surgery. More than 60 percent of operations are ...
Cached Medicine News:Health News:Apartment dwellers often subjected to neighbors' tobacco smoke 2Health News:Better health in adulthood starts with early prevention in childhood 2Health News:Taking Away Car Keys Can Be Tough for Older Drivers 2Health News:Moffitt Cancer Center researchers working at frontiers of melanoma research 2Health News:Blood Clot Risk for Outpatients Needs More Attention: Study 2
Endotracheal Tube Stylet- Adult, Copper, Malleable, Non-Sterile, Latex Free, Suitable for tubes 5.0 mm I.D. or larger....
Bivona® stylets are manufactured of malleable stainless steel wire. The length can be adjusted by sliding the attached silicone stopper. The Blue Line® tracheal tube introducer (bougie) is de...
... of flexible lighting products. The first is ... different sizes 5", 10", and 15" (refers ... light). These lights are for use in ... ,The second group of flexible lights is ...
... manufactures two groups of flexible lighting products. ... non-sterile in three different sizes 5", 10", ... portion of the light). These lights are ... is needed., ,The second group of ...
Medicine Products: